Feb 2018

QUEENSLAND LEADS WITH WORLD-FIRST MEDICINAL CANNABIS TRIAL

A Queensland trial will evaluate the benefits of medicinal cannabis for symptom relief in cancer patients receiving palliative care. The clinical trial is funded by the Medical Research Future Fund (MRFF), a landmark fund established by the Australian Government supporting clinical trials for rare diseases and unmet medical needs.

The study is the first clinical trial worldwide to rigorously evaluate the efficacy, safety and acceptability of medicinal cannabinoids for symptom relief in advanced cancer patients receiving palliative care. The study will be a randomised, blinded, placebo controlled trial that will define the role of medicinal cannabis in the care of these patients.

Read the article here.

 

One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.

READ MORE >

In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.

READ MORE >

What’s most important in business – purpose or profit? At ANTG we get to achieve both.

READ MORE >

We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.

LEARN ABOUT ANTG HERE >